Patents by Inventor Tie-Lin Wang

Tie-Lin Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 11 BETA-HSD1 MODULATORS
    Publication number: 20100105675
    Abstract: A compound according to Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R11, L1 and X are as defined in the specification, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: March 13, 2009
    Publication date: April 29, 2010
    Applicant: Exelixis, Inc.
    Inventors: Richard Martin, Brenton Flatt, Jackline Dalgard, Venkataiah Bollu, Ping Huang, Raju Mohan, Edwin Schweiger, Tie Lin Wang
  • IMIDAZOLE BASED LXR MODULATORS
    Publication number: 20100075964
    Abstract: Compounds of the invention, such as compounds of Formulae IIa, IIb, IIc or IId, and pharmaceutically acceptable salts, isomers, and prodrugs thereof, are useful as modulators of the activity of liver X receptors, where R1, R2, R21, R3 and G are defined herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.
    Type: Application
    Filed: June 26, 2006
    Publication date: March 25, 2010
    Applicant: EXELIXIS, INC.
    Inventors: Brett B. Busch, Brenton T. Flatt, Xiao-Hui Gu, Shao-Po Lu, Richard Martin, Raju Mohan, Michael Charles Nyman, Edwin Schweiger, William C. Stevens, Jr., Tie-Lin Wang, Yinong Xie
  • LXR and FXR Modulators
    Publication number: 20100069367
    Abstract: Compounds of the invention are disclosed, such as compounds of formulae LX-LXIV, and pharmaceutically acceptable salts, isomers, or prodrugs thereof, which are useful as modulators of the activity of liver X receptors (LXR) and Farnesoid X receptors (FXR), where R00, R200, R400, R500, J11, J21, G1, G21, and Q are defined herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.
    Type: Application
    Filed: December 7, 2007
    Publication date: March 18, 2010
    Applicant: EXELIXIS, INC.
    Inventors: Brant Clayton Boren, Brett B. Busch, Xiao-Hui Gu, Vasu Jammalamadaka, Shao Po Lu, Richard Martin, Raju Mohan, Edwin Schweiger, William C. Stevens, Tie-Lin Wang, Yinong Xie, Wei Xu
  • Azepinoindole and Pyridoindole Derivatives as Pharmaceutical Agents
    Publication number: 20090326218
    Abstract: Compounds, compositions and methods for modulating the activity of receptors are provided. In particular compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors.
    Type: Application
    Filed: January 29, 2009
    Publication date: December 31, 2009
    Applicant: EXELIXIS, INC.
    Inventors: Richard Martin, Tie-Lin Wang, Brenton T. Flatt, Xiao-Hui Gu, Ronald Griffith
  • 11 Beta-HSD1 Modulators
    Publication number: 20090247515
    Abstract: A compound according to Formula A: or a pharmaceutically acceptable salt thereof, wherein R11, G1 and G2 are as defined in the specification, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: March 13, 2009
    Publication date: October 1, 2009
    Applicant: Exelixis, Inc.
    Inventors: Richard Martin, Brenton T. Flatt, Jackline Eve Dalgard, Venkataiah Bollu, Ping Huang, Raju Mohan, Edwin Schweiger, Tie-Lin Wang
  • Azepinoindole derivatives as pharmaceutical agents
    Patent number: 7595311
    Abstract: Compounds, compositions and methods for modulating the activity of receptors are provided. In particular, compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors.
    Type: Grant
    Filed: December 2, 2003
    Date of Patent: September 29, 2009
    Assignee: Exelixis, Inc.
    Inventors: Brett Busch, Brenton T Flatt, Xiao-Hui Gu, Richard Martin, Raju Mohan, Tie-Lin Wang, Jason H Wu
  • Azepinoindole Derivatives As Pharmaceutical Agents
    Publication number: 20090203577
    Abstract: The present invention relates to compounds of formula I, which exhibit affinity for the farnesoid X receptor.
    Type: Application
    Filed: December 12, 2006
    Publication date: August 13, 2009
    Applicant: EXELIXIS, INC.
    Inventors: Tae-Gon Baik, Chris A. Buhr, Brett B. Busch, Diva Sze-Ming Chan, Brenton T. Flatt, Xiao-Hui Gu, Vasu Jammalamadaka, Richard George Khoury, Katherine Lara, Sunghoon Ma, Richard Martin, Raju Mohan, John M. Nuss, Jason Jevious Parks, Jason H. Wu, Bryan K. S. Yeung, Wei Xu, Tie-Lin Wang, Longcheng Wang
  • Azepinoindole and pyridoindole derivatives as pharmaceutical agents
    Patent number: 7485634
    Abstract: Compounds, compositions and methods for modulating the activity of receptors are provided. In particular compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors.
    Type: Grant
    Filed: May 27, 2003
    Date of Patent: February 3, 2009
    Assignee: Exelixis, Inc.
    Inventors: Richard Martin, Tie-Lin Wang, Brenton T Flatt, Xiao-Hui Gu, Ronald Griffith
  • Pyrrole Derivatives As Pharmaceutical Agents
    Publication number: 20080234270
    Abstract: Compounds, compositions and methods for modulating the activity of receptors are provided. In particular compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors.
    Type: Application
    Filed: July 30, 2005
    Publication date: September 25, 2008
    Applicant: EXELIXIS, INC.
    Inventors: Lynne Canne Bannen, Jeff Chen, Lisa Esther Dalrymple, Brenton T. Flatt, Timothy Patrick Forsyth, Xiao-Hui Gu, Morrison B. Mac, Larry W. Mann, Grace Mann, Richard Martin, Raju Mohan, Brett Murphy, Michael Charles Nyman, William C. Stevens, Tie-Lin Wang, Yong Wang, Jason H. Wu
  • Azepine derivaties as pharmaceutical agents
    Publication number: 20070015746
    Abstract: Compounds, compositions and methods are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder related to the activity of the receptors.
    Type: Application
    Filed: July 23, 2004
    Publication date: January 18, 2007
    Applicant: X-CEPTOR THERAPEUTICS INC.
    Inventors: Richard Martin, Tie-Lin Wang, Brenton Flatt, Xiao-Hui Gu
  • Heterocyclic modulators of nuclear receptors
    Patent number: 7115640
    Abstract: Compounds, compositions and methods for modulating the activity of nuclear receptors are provided. In particular, heterocyclic compounds are provided for modulating the activity of farnesoid X receptor (FXR), liver X receptor (LXR) and/or orphan nuclear receptors. In certain embodiments, the compounds are thiazolidinone derivatives.
    Type: Grant
    Filed: November 18, 2003
    Date of Patent: October 3, 2006
    Assignee: X-Ceptor Therapeutics, Inc.
    Inventors: Richard Martin, Brenton T Flatt, Jeffrey D Kahl, Tie-Lin Wang
  • Azepinoindole derivatives as pharmaceutical agents
    Publication number: 20050054634
    Abstract: Compounds, compositions and methods for modulating the activity of receptors are provided. In particular, compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors.
    Type: Application
    Filed: December 2, 2003
    Publication date: March 10, 2005
    Inventors: Brett Busch, Brenton Flatt, Xiao-Hui Gu, Richard Martin, Raju Mohan, Tie-Lin Wang, Jason Wu
  • Heterocyclic modulators of nuclear receptors
    Publication number: 20040180942
    Abstract: Compounds, compositions and methods for modulating the activity of nuclear receptors are provided. In particular, heterocyclic compounds are provided for modulating the activity of farnesoid X receptor (FXR), liver X receptor (LXR) and/or orphan nuclear receptors. In certain embodiments, the compounds are thiazolidinone derivatives.
    Type: Application
    Filed: November 18, 2003
    Publication date: September 16, 2004
    Applicant: X-Ceptor Therapeutics, Inc.
    Inventors: Richard Martin, Brenton Todd Flatt, Jeffrey Dean Kahl, Tie-Lin Wang
  • Heterocyclic modulators of nuclear receptors
    Patent number: 6696473
    Abstract: Compounds, compositions and methods for modulating the activity of nuclear receptors are provided. In particular, heterocyclic compounds are provided for modulating the activity of farnesoid X receptor (FXR), liver X receptor (LXR) and/or orphan nuclear receptors. In certain embodiments, the compounds are thiazolidinone derivatives.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: February 24, 2004
    Assignee: X-Ceptor Therapeutics, Inc.
    Inventors: Richard Martin, Brenton Todd Flatt, Jeffrey Dean Kahl, Tie-Lin Wang
  • Azepinoindole and pyridoindole derivatives as pharmaceutical agents
    Publication number: 20040023947
    Abstract: Compounds, compositions and methods for modulating the activity of receptors are provided. In particular compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors.
    Type: Application
    Filed: May 27, 2003
    Publication date: February 5, 2004
    Applicant: X-Ceptor Therapeutics Inc.
    Inventors: Richard Martin, Tie-Lin Wang, Brenton T. Flatt, Xiao-Hui Gu, Ronald Griffith
  • Heterocyclic modulators of nuclear receptors
    Publication number: 20030212111
    Abstract: Compounds, compositions and methods for modulating the activity of nuclear receptors are provided. In particular, heterocyclic compounds are provided for modulating the activity of farnesoid X receptor (FXR), liver X receptor (LXR) and/or orphan nuclear receptors. In certain embodiments, the compounds are thiazolidinone derivatives.
    Type: Application
    Filed: December 20, 2002
    Publication date: November 13, 2003
    Inventors: Richard Martin, Brenton Todd Flatt, Jeffrey Dean Kahl, Tie-Lin Wang
  • Water-soluble derivatives of camptothecin/homocamptothecin
    Patent number: 6291676
    Abstract: Camptothecin and homocamptothecin analogs and derivatives are provided incorporating alkylamine and polyalkylamine moieties.
    Type: Grant
    Filed: March 2, 2000
    Date of Patent: September 18, 2001
    Assignee: University of Kentucky Research Foundation
    Inventors: Thomas G. Burke, Ayhan S. Demir, Cihangir Tanyeli, Ashok J. Chavan, Tie-Lin Wang, Yves Pommier